|Articles|September 2, 2016

Pharmaceutical Technology

  • Pharmaceutical Technology-09-02-2016
  • Volume 40
  • Issue 9

Analyzer Automates Cell-Culture Chemistry Analysis

The BioProfile FLEX 2 from Nova Biomedical is a cell-culture chemistry analyzer that allows for automated cell-culture analysis for small-volume culture systems.

The BioProfile FLEX 2 from Nova Biomedical is a cell-culture chemistry analyzer that allows for automated cell-culture analysis for small-volume culture systems. The system incorporates Nova’s MicroSensor Card technology, which minimizes sensor maintenance. The FLEX 2 provides analysis of 16-cell culture chemistries including Gluc, Lac, Gln, Glu, NH4+, Na+, K+, Ca++, pH, pCO2, pO2, osmolality by freezing point depression, and total and viable cell density and viability by trypan blue dye exclusion method. The full panel of tests can be run in under four minutes with 265 microliters of sample, and users can select from manual sampling or two modes for batch sampling: 96-well plates or the built-in 24-position tray. Designed for small volume, early-stage cell culture development through GMP manufacturing, BioProfile FLEX 2 provides 21 CFR Part 11 compliance, OPC connectivity, full networking functionality, and support with all validation needs.

Nova Biomedical
 

Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.